In vivo studies regarding biochemical, molecular biological, and histopathological changes in cancer tissues have been widely performed by the administration of carcinogens in rodents. In these established methods, dissection of the animal following sacrifice must be carried out. Exosomes are cell-derived vesicles that are present in all body fluids and these vesicles have specific roles within cells. Thus, much attention is given to the clinical application of exosomes that can possibly be used for prediction and therapy and as biomarkers related to cancer. To develop a new tool for monitoring in vivo genetic alterations, as a result of carcinogenesis, without the need for frequent euthanasia, researchers from the Occupational Safety and Health Research Institute, Korea performed quantitative measurement of exosomes in Mlg2908 murine lung fibroblasts and LA-4 and KLN 205 murine lung cancer cells using fluorescence-activated cell sorting. They detected an increase in CD63-specific exosomes in LA-4 lung cancer cells. This result is able to be applied to the classification of cancer-specific proteins and miRNA as diagnostic markers.
Two-dimensional plots of the exosome fluorescence-activated cell sorting analysis
Exosomes were isolated and purified from murine Mlg 2908 lung fibroblasts, KLN 205 lung squamous cell carcinoma cells, and LA-4 murine lung adenoma cells with (A) CD9 antibody and (B) CD63 antibody. Purifed exosomes were analyzed using fluorescence-activated cell sorting (FACS). SSC, scattered light; FSC, forward-scattered light; FITC, fluorescein isothiocyanate.